- No trial has tested "microdosing," but dose-finding trials show lower doses work less well: in SURMOUNT-1, tirzepatide 5 mg cut weight by 15.0% over 72 weeks vs 20.9% on 15 mg and 3.1% on placebo.3
- Lower doses cause somewhat fewer stomach side effects, but the gap is smaller than many expect: nausea affected 25% on Zepbound 5 mg vs 28% on 15 mg in the label's pooled trials.9
- The biggest documented risks come from measuring small doses from vials or pens in ways they were not designed for. The FDA has reported errors of 5 to 20 times the intended dose with compounded semaglutide.7
- This article gives no doses to try. Any change to your dose is a decision to make with your prescriber.
What do people mean by GLP-1 microdosing?
"Microdosing" is an informal term, not a medical one. People use it for taking a GLP-1 medicine such as semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro) below the doses on the label, or spacing doses further apart. A 2026 commentary in Expert Opinion on Pharmacotherapy says it is typically described as 25% to 50% of the manufacturer's recommended starting dose, or extended dosing intervals. The reasons people give include fewer side effects, lower cost, and stretching supply during shortages.1
The same commentary is blunt: high-quality evidence is essentially absent. Early reports of less nausea and modest weight loss come from patient communities, telehealth programs and clinician anecdotes, not trials.1 Reddit threads are a big part of that conversation, but they cannot tell you how many people tried it and quietly stopped.
What dose-finding trials show about lower doses
Drug makers test several doses before choosing which to bring to market. Those trials are the best evidence we have on what lower doses do, even though none was designed to test microdosing.
Tirzepatide: SURMOUNT-1
This 72-week trial randomly assigned 2,539 adults with obesity, or overweight plus a weight-related condition, and without diabetes, to weekly tirzepatide 5 mg, 10 mg or 15 mg, or placebo.3
The lowest maintenance dose still worked well, but average weight loss on the higher doses was about 30% to 40% greater. Side effects led to stopping treatment in 4.3% on 5 mg, 7.1% on 10 mg, 6.2% on 15 mg and 2.6% on placebo.3
An earlier 26-week phase 2 trial in 316 adults with type 2 diabetes included a 1 mg dose. Blood sugar (HbA1c) fell by 1.06 points on 1 mg and 1.94 points on 15 mg, vs 0.06 on placebo. Weight change ranged from −0.9 kg to −11.3 kg across the doses, rising with dose.4
Semaglutide: the phase 2 dose-finding trial
Before Wegovy, Novo Nordisk tested daily semaglutide injections at five doses in 957 adults with obesity and without diabetes for 52 weeks.2
| Daily dose in the trial | Average weight change at 52 weeks |
|---|---|
| Placebo | −2.3% |
| Semaglutide 0.05 mg | −6.0% |
| Semaglutide 0.1 mg | −8.6% |
| Semaglutide 0.2 mg | −11.6% |
| Semaglutide 0.3 mg | −11.2% |
| Semaglutide 0.4 mg | −13.8% |
| Liraglutide 3.0 mg (comparison) | −7.8% |
Even the lowest dose beat placebo, and weight loss generally rose with dose. Stomach side effects, mainly nausea, were dose-related.2
In STEP 2, 1,210 adults with type 2 diabetes and overweight or obesity took weekly semaglutide 2.4 mg, 1.0 mg or placebo for 68 weeks. Weight fell 9.6% on 2.4 mg vs 3.4% on placebo. Stomach side effects affected 63.5% on 2.4 mg, 57.5% on 1.0 mg and 34.3% on placebo.5
Microdosing vs full dose: what about side effects?
Side effects are the main reason people cite for going low. The trial data suggest a lower dose helps, but less than many hope:
The labels already build in a slow start. Zepbound starts at 2.5 mg, which the label says is for treatment initiation and is not approved as a maintenance dose. Wegovy starts at 0.25 mg and steps up every 4 weeks, and its label says that if a dose is not tolerated during escalation, prescribers can consider delaying the next step by 4 weeks.9 Those are instructions to prescribers, written into the label. For ways to manage nausea, see GLP-1 nausea and stomach side effects.
Real-world data on staying at the starting dose
A 2026 health-record study looked at people who stayed on the starting dose for at least 6 months: 814 on semaglutide 0.25 mg and 1,016 on tirzepatide 2.5 mg. Average weight change at 12 months was −2.2% and −5.5%. This is observational data, and the authors note that staying on a starting dose does not mean someone was intentionally microdosing.6
GLP-1 microdosing side effects and risks
The risks people cite are less about the low dose itself and more about how it is measured and where the medicine comes from.
- Measuring from vials. The FDA's July 2024 alert described people drawing up 5 to 20 times the intended dose of compounded semaglutide from multi-dose vials, often because of confusion between milliliters, milligrams and "units" on insulin syringes. Reported problems included nausea, vomiting, fainting, dehydration, acute pancreatitis and gallstones, and some people were hospitalized. The FDA notes semaglutide's half-life is about one week, so overdose symptoms can last.7
- Counting pen clicks. Some people try to dial partial doses on multi-dose pens. The Ozempic Instructions for Use say to use the dose counter and "do not count the pen clicks." The label also says pens must never be shared, even with a new needle.9
- Compounded and unregulated products. A 2026 report for nurse practitioners describes people turning to compounded vials and online "research-grade" peptides to microdose, and flags pen manipulation and medication sharing as safety risks.8 Compounded drugs are not FDA-approved. See compounded semaglutide and tirzepatide for what the FDA says.
Can microdosing help with food noise?
Many microdosing posts say a small dose quiets "food noise," the constant thinking about food. We found no trial that measured food noise at low or below-label doses. What exists is the dose-finding data above, which measured weight and blood sugar, plus personal reports. For what studies say about food noise at standard doses, see GLP-1 and food noise.
Common questions
Does GLP-1 microdosing work?
No clinical trial has tested microdosing as such, and a 2026 expert commentary says high-quality evidence is essentially absent. Dose-finding trials show lower doses still caused weight loss, though less: in SURMOUNT-1, adults with obesity lost 15.0% of body weight on tirzepatide 5 mg over 72 weeks vs 3.1% on placebo.
Is microdosing better than the full dose?
For weight loss, higher doses did better in trials. In SURMOUNT-1, adults with obesity lost 15.0% on tirzepatide 5 mg, 19.5% on 10 mg and 20.9% on 15 mg over 72 weeks. Which dose is right for a person is a decision for their prescriber.
Does microdosing reduce GLP-1 side effects?
Lower doses cause somewhat fewer side effects, but not none. In the Zepbound label's pooled weight trials, nausea affected 25% of adults on 5 mg, 29% on 10 mg and 28% on 15 mg, vs 8% on placebo. In STEP 2, stomach side effects affected 57.5% on semaglutide 1.0 mg vs 63.5% on 2.4 mg.
What are the risks of microdosing compounded semaglutide?
Measuring small doses from multi-dose vials can go wrong. In a July 2024 alert, the FDA reported people taking 5 to 20 times the intended dose of compounded semaglutide, often because of confusion between milliliters, milligrams and syringe units, with some needing hospital care.
Can microdosing help with food noise?
No trial has measured food noise at low or below-label doses, so claims are based on personal reports. A 2026 commentary describes microdosing as typically 25% to 50% of the manufacturer's starting dose and says early reports of benefit come from patient communities and clinician anecdotes, not trials.
Sources
- Beck H, Clements JN. Considerations and challenges in microdosing of GLP-1-based receptor agonists. Expert Opin Pharmacother. 2026:1-4 (online ahead of print). doi:10.1080/14656566.2026.2740393 · PubMed
- O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637-649. doi:10.1016/S0140-6736(18)31773-2 · PubMed
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 · PubMed
- Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180-2193. doi:10.1016/S0140-6736(18)32260-8 · PubMed
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0 · PubMed
- Murugadoss K, Venkatakrishnan AJ, Soundararajan V. Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide. Biol Methods Protoc. 2026;11(1):bpag048. doi:10.1093/biomethods/bpag048 · Full text (PMC)
- US Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. Content current as of July 26, 2024. fda.gov
- Trainer N. The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. J Am Assoc Nurse Pract. 2026 (online ahead of print). doi:10.1097/JXX.0000000000001296 · PubMed
- US prescribing information: ZEPBOUND (revised 08/2026; sections 2.1 and 6.1), WEGOVY (revised 06/2026; section 2.2) and OZEMPIC (revised 01/2025; section 5.4 and Instructions for Use), DailyMed, checked November 2026.
